Immunotherapy may replace chemo in anal cancer treatment
NCT ID NCT07692152
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether the immunotherapy drug sintilimab can replace the chemotherapy drug mitomycin in standard chemoradiation for limited-stage anal squamous cell carcinoma. About 350 patients who have not yet been treated will receive either the standard regimen (radiation with capecitabine and mitomycin) or the experimental regimen (radiation with capecitabine and sintilimab). The study aims to see if the experimental group has a similar tumor response rate but fewer severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab
- What this could lead to
- If successful, this could offer a less toxic treatment option for limited-stage anal cancer by replacing chemotherapy with immunotherapy.
- What could go wrong
- This is an early-phase trial, and the experimental treatment may not be as effective as the standard. Immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL SQUAMOUS CELL CARCINOMA, LIMITED-STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen
RECRUITINGShenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••